Pay in 4 interest-free payments of $6.05 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
The goal isnt to copy someone elses lips but to highlight what already suits your face best
You may be a good candidate if you are an adult with Type 2 diabetes who also has one of the following: Heart disease or multiple risk factors for heart disease Chronic kidney disease A body mass index (BMI) over 27 ( This means your weight is generally higher than whats considered healthy for your height .) For weight management, you may be a good candidate if you are an adult with: A BMI over 30 A BMI over 27 with one weight-related condition, such as: High blood pressure High cholesterol Type 2 diabetes Q: Who should not take a GLP-1 medication
Following established handling guidelines may help maintain peptide stability throughout the product lifecycle
Where to find GLP-1 friendly options and what they cost Here's a breakdown of what major chains are currently offering: Chipotle Chipotle is one of the first major chains to lean into the trend
- Kurt thought there was a 50% chance all GLP-1 compounding would end in the next 6 months (both 503A and 503B) - Did not mention direct communication from the FDA telling them to stop compounding GLP-1s - ProRx felt it was time to stop due to the end of the shortage in March 2025, and did not feel influenced by the April 1 FDA statement - Kurt thinks 503B production of GLP-1s are underreported and much larger than thought - 503As can't take care of the compounded GLP-1 market at their current capacity - We both have concerns about patient access without compounded GLP-1s and worry it will send more patients to the grey market for RUO injections that don't have the same level of sterility and regulation To view or add a comment, sign in Yesterday the FDA proposed removing GLP-1s from the 503B bulk list, and I spoke to Kurt Lunkwitz from ProRx to talk about changes to GLP-1 compounding
